BRD4 and Cancer: Going beyond transcriptional regulation

Benedetta Donati, Eugenia Lorenzini, Alessia Ciarrocchi

Research output: Contribution to journalReview article

Abstract

BRD4, member of the Bromodomain and Extraterminal (BET) protein family, is largely acknowledged in cancer for its role in super-enhancers (SEs) organization and oncogenes expression regulation. Inhibition of BRD4 shortcuts the communication between SEs and target promoters with a subsequent cell-specific repression of oncogenes to which cancer cells are addicted and cell death. To date, this is the most credited mechanism of action of BET inhibitors, a class of small molecules targeting BET proteins which are currently in clinical trials in several cancer settings. However, recent evidence indicates that BRD4 relevance in cancer goes beyond its role in transcription regulation and identifies this protein as a keeper of genome stability. Indeed, a non-transcriptional role of BRD4 in controlling DNA damage checkpoint activation and repair as well as telomere maintenance has been proposed, throwing new lights into the multiple functions of this protein and opening new perspectives on the use of BETi in cancer. Here we discuss the current available information on non-canonical, non-transcriptional functions of BRD4 and on their implications in cancer biology. Integrating this information with the already known BRD4 role in gene expression regulation, we propose a "common" model to explain BRD4 genomic function. Furthermore, in light of the transversal function of BRD4, we provide new interpretation for the cytotoxic activity of BETi and we discuss new possibilities for a wide and focused employment of these drugs in clinical settings.

Original languageEnglish
Article number164
JournalMolecular Cancer
Volume17
Issue number1
DOIs
Publication statusPublished - Nov 22 2018

Fingerprint

Neoplasms
Oncogenes
Proteins
Genomic Instability
Telomere
Gene Expression Regulation
DNA Damage
Cell Death
Maintenance
Clinical Trials
Organizations
Light
Pharmaceutical Preparations

Keywords

  • BET inhibitors
  • BRD4
  • Cancer
  • DNA damage response
  • Telomere regulation
  • Transcriptional regulation
  • Unconventional function

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Cancer Research

Cite this

BRD4 and Cancer : Going beyond transcriptional regulation. / Donati, Benedetta; Lorenzini, Eugenia; Ciarrocchi, Alessia.

In: Molecular Cancer, Vol. 17, No. 1, 164, 22.11.2018.

Research output: Contribution to journalReview article

Donati, Benedetta ; Lorenzini, Eugenia ; Ciarrocchi, Alessia. / BRD4 and Cancer : Going beyond transcriptional regulation. In: Molecular Cancer. 2018 ; Vol. 17, No. 1.
@article{f8697c3cda8d47179f17129de9672bee,
title = "BRD4 and Cancer: Going beyond transcriptional regulation",
abstract = "BRD4, member of the Bromodomain and Extraterminal (BET) protein family, is largely acknowledged in cancer for its role in super-enhancers (SEs) organization and oncogenes expression regulation. Inhibition of BRD4 shortcuts the communication between SEs and target promoters with a subsequent cell-specific repression of oncogenes to which cancer cells are addicted and cell death. To date, this is the most credited mechanism of action of BET inhibitors, a class of small molecules targeting BET proteins which are currently in clinical trials in several cancer settings. However, recent evidence indicates that BRD4 relevance in cancer goes beyond its role in transcription regulation and identifies this protein as a keeper of genome stability. Indeed, a non-transcriptional role of BRD4 in controlling DNA damage checkpoint activation and repair as well as telomere maintenance has been proposed, throwing new lights into the multiple functions of this protein and opening new perspectives on the use of BETi in cancer. Here we discuss the current available information on non-canonical, non-transcriptional functions of BRD4 and on their implications in cancer biology. Integrating this information with the already known BRD4 role in gene expression regulation, we propose a {"}common{"} model to explain BRD4 genomic function. Furthermore, in light of the transversal function of BRD4, we provide new interpretation for the cytotoxic activity of BETi and we discuss new possibilities for a wide and focused employment of these drugs in clinical settings.",
keywords = "BET inhibitors, BRD4, Cancer, DNA damage response, Telomere regulation, Transcriptional regulation, Unconventional function",
author = "Benedetta Donati and Eugenia Lorenzini and Alessia Ciarrocchi",
year = "2018",
month = "11",
day = "22",
doi = "10.1186/s12943-018-0915-9",
language = "English",
volume = "17",
journal = "Molecular Cancer",
issn = "1476-4598",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - BRD4 and Cancer

T2 - Going beyond transcriptional regulation

AU - Donati, Benedetta

AU - Lorenzini, Eugenia

AU - Ciarrocchi, Alessia

PY - 2018/11/22

Y1 - 2018/11/22

N2 - BRD4, member of the Bromodomain and Extraterminal (BET) protein family, is largely acknowledged in cancer for its role in super-enhancers (SEs) organization and oncogenes expression regulation. Inhibition of BRD4 shortcuts the communication between SEs and target promoters with a subsequent cell-specific repression of oncogenes to which cancer cells are addicted and cell death. To date, this is the most credited mechanism of action of BET inhibitors, a class of small molecules targeting BET proteins which are currently in clinical trials in several cancer settings. However, recent evidence indicates that BRD4 relevance in cancer goes beyond its role in transcription regulation and identifies this protein as a keeper of genome stability. Indeed, a non-transcriptional role of BRD4 in controlling DNA damage checkpoint activation and repair as well as telomere maintenance has been proposed, throwing new lights into the multiple functions of this protein and opening new perspectives on the use of BETi in cancer. Here we discuss the current available information on non-canonical, non-transcriptional functions of BRD4 and on their implications in cancer biology. Integrating this information with the already known BRD4 role in gene expression regulation, we propose a "common" model to explain BRD4 genomic function. Furthermore, in light of the transversal function of BRD4, we provide new interpretation for the cytotoxic activity of BETi and we discuss new possibilities for a wide and focused employment of these drugs in clinical settings.

AB - BRD4, member of the Bromodomain and Extraterminal (BET) protein family, is largely acknowledged in cancer for its role in super-enhancers (SEs) organization and oncogenes expression regulation. Inhibition of BRD4 shortcuts the communication between SEs and target promoters with a subsequent cell-specific repression of oncogenes to which cancer cells are addicted and cell death. To date, this is the most credited mechanism of action of BET inhibitors, a class of small molecules targeting BET proteins which are currently in clinical trials in several cancer settings. However, recent evidence indicates that BRD4 relevance in cancer goes beyond its role in transcription regulation and identifies this protein as a keeper of genome stability. Indeed, a non-transcriptional role of BRD4 in controlling DNA damage checkpoint activation and repair as well as telomere maintenance has been proposed, throwing new lights into the multiple functions of this protein and opening new perspectives on the use of BETi in cancer. Here we discuss the current available information on non-canonical, non-transcriptional functions of BRD4 and on their implications in cancer biology. Integrating this information with the already known BRD4 role in gene expression regulation, we propose a "common" model to explain BRD4 genomic function. Furthermore, in light of the transversal function of BRD4, we provide new interpretation for the cytotoxic activity of BETi and we discuss new possibilities for a wide and focused employment of these drugs in clinical settings.

KW - BET inhibitors

KW - BRD4

KW - Cancer

KW - DNA damage response

KW - Telomere regulation

KW - Transcriptional regulation

KW - Unconventional function

UR - http://www.scopus.com/inward/record.url?scp=85057073685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057073685&partnerID=8YFLogxK

U2 - 10.1186/s12943-018-0915-9

DO - 10.1186/s12943-018-0915-9

M3 - Review article

C2 - 30466442

AN - SCOPUS:85057073685

VL - 17

JO - Molecular Cancer

JF - Molecular Cancer

SN - 1476-4598

IS - 1

M1 - 164

ER -